

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

Claims 1-17. (Canceled)

18. (Currently amended) A monoclonal antibody ~~or fragment thereof~~ obtainable from a hybridoma cell of, ~~or derived from~~, ECACC Deposit No. 03073001, or an antigen-binding fragment of said monoclonal antibody.

19. (Currently amended) A method of detecting at least one of an astrocytoma cell and a primary breast carcinoma cell in a sample of human cells, which method comprises the step of contacting the cell sample with an antibody according to Claim 18, or a an antigen-binding fragment thereof, and detecting those cells which have bound the antibody or fragment, wherein binding of the antibody or the fragment to a cell is indicative of at least one of an astrocytoma cell and a primary breast carcinoma cell.

20.-22. (Canceled)

23. (Currently amended) A diagnostic kit for diagnosing the presence of a cell selected from the group consisting of: astrocytoma cells; malignant melanoma secondary tumour cells; and primary breast carcinoma cells, the kit comprising a primary antibody according to Claim 18, or a an antigen-binding fragment thereof.

24. (Currently amended) The diagnostic kit as claimed in Claim 23 in which the antibody or antigen-binding fragment comprises a detectable label.

25. (Currently amended) The diagnostic kit as claimed in Claim 23 in which the kit comprises a secondary antibody which specifically binds the primary antibody or antigen-binding fragment of the primary antibody, which secondary antibody comprises a detectable label.

26. (Currently amended) A biological targeting device comprising an antibody according to Claim 18, or a an antigen-binding fragment thereof, and a therapeutic ligand.

27. (Canceled)

28. (Currently amended) A method of treating cancer in an individual by inducing apoptosis in cells in the individual which express an MQ1 protein, which method comprises a step of treating an individual with an antibody of Claim 18, or a an antigen-binding fragment thereof.

29. (Previously presented) The method according to Claim 28 in which the cancer is selected from the group consisting of malignant astrocytomas; malignant melanoma secondary tumours; and primary breast carcinomas.

30. (Canceled)

31. (Previously presented) The method as claimed in Claim 28 in which the antibody is humanised.

32.-38. (Canceled)

39. (new) A hybridoma cell of ECACC Deposit No. 03073001.